Characteristics of the Plasmodium falciparum PK5 ATP-binding site: Implications for the design of novel antimalarial agents

Journal of Molecular Graphics and Modelling

Volumn 22, Issue 3, 2004, Pages 241-247

  Keenan, Susan M ^a   Welsh, William J ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

CDK; Drug design; Inhibitors; Malaria; P. falciparum PK 5 (PfPK5)

Indexed keywords

ADENOSINETRIPHOSPHATE; CELLS; CHEMOTHERAPY; DRUG PRODUCTS; ENZYMES; MALARIA CONTROL; X RAY CRYSTALLOGRAPHY;

MAMMALIAN CELL CYCLES;

PROTOZOA;

ADENOSINE TRIPHOSPHATE; ANTIMALARIAL AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; ISOENZYME; PROTEIN KINASE 5; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BRAIN MALARIA; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME ANALYSIS; ENZYME STRUCTURE; LIFE CYCLE; PHARMACOPHORE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

MAMMALIA; PLASMODIUM FALCIPARUM;

EID: 0242474624     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2003.09.002     Document Type: Article

References (25)

1. Gray N.S., et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 281:1998;533-538.
2. World Health Organization, 2002.
3. Ross-Macdonald P.B., et al. Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum. Eur. J. Biochem. 220:1994;693-701.
4. Li Z., et al. Influence of human p16(INK4) and p21(CIP1) on the in vitro activity of recombinant Plasmodium falciparum cyclin-dependent protein kinases. Biochem. Biophys. Res. Commun. 288:2001;1207-1211.
5. Kappes B., Doerig C.D., Graeser R. An overview of Plasmodium protein kinases. Parasitol. Today. 15:1999;449-454.
6. Doerig C., Endicott J., Chakrabarti D. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int. J. Parasitol. 32:2002;1575-1585.
7. Graeser R., Franklin R.M., Kappes B. Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol. Biochem. Parasitol. 79:1996;125-127.
8. Gu Y., Rosenblatt J., Morgan D.O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 11:1992;3995-4005.
9. Le Roch K., et al. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J. Biol. Chem. 275:2000;8952-8958.
10. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
11. Harmse L., et al. Structure-Activity Relationships and Inhibitory Effects of Various Purine Derivatives on the in vitro growth of Plasmodium Falciparum. Biochem. Pharmacol. 62:2001;341-348.
12. Graeser R., et al. Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles. Mol. Biochem. Parasitol. 82:1996;37-49.
13. Russo A.A., Jeffrey P.D., Pavletich N.P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 3:1996;696-700.
14. Rodriguez R., et al. Homology modeling, model and software evaluation: three related resources. Bioinformatics. 14:1998;523-528.
15. Jones G., et al. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267:1997;727-748.
16. Sachs J., Malaney P. The economic and social burden of malaria. Nature. 415:2002;680-685.
17. Pines J. The cell cycle kinases. Seminars Cancer Biol. 5:1994;305-313.
18. Taylor S.S., Radzio-Andzelm E. Three protein kinase structures define a common motif. Structure. 2:1994;345-355.
19. Taylor S.S., et al. Structural framework for the protein kinase family. Ann. Rev. Cell Biol. 8:1992;429-462.
20. Gray N., et al. ATP-site directed inhibitors of cyclin-dependent kinases. Current Med. Chem. 6:1999;859-875.
21. Hoessel R., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol. 1:1999;60-67.
22. Meijer L., et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7:2000;51-63.
23. Barvian M., et al. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. 43:2000;4606-4616.
24. Kim K.S., et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. J. Med. Chem. 43:2000;4126-4134.
25. Soni R., et al. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. 275:2000;877-884.